Ce3 is a full-service CRO committed to working with biotechnology companies on emerging therapies and technologies to improve patient lives. Our experience in working exclusively with Biotechs has refined and leveraged our tools and skills to easily accommodate the special requests and customization required by this dynamic environment.
Our focus is on early phase development. We know the level of agility, detail, and precision such studies require. Ce3 supports clients in the most cost-effective manner with quality data to facilitate timely decision making. We can execute faster, easier, and better to meet biotech and investor needs.
Ce3’s depth of experience includes Immuno-Oncology (inclusive of CAR-T), Gene Therapy (multiple therapeutic indications), and other innovative therapies. Our expertise is in Oncology clinical research and clinical trial execution: • First in Human • Dose Escalation • Cohort Management • Complex and adaptive study designs.
Our name, Ce3, represents our core values and serves as the foundation of our operations: a collaborative approach in managing your studies while delivering experience, efficiency and excellence!